Bandingkan Harga & Kinerja Indofarma Tbk. (INAF) vs Reksa Dana Premier ETF Indonesia Stated-Owned Companies (XISC)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Indofarma Tbk. dan Reksa Dana Premier ETF Indonesia Stated-Owned Companies: Indofarma Tbk. diperdagangkan di Rp126 (kapitalisasi pasar 390,51 M), sedangkan Reksa Dana Premier ETF Indonesia Stated-Owned Companies diperdagangkan di Rp805 (kapitalisasi pasar 719 M, volume 24 jam 1,6 rb). Perbedaan utamanya: Reksa Dana Premier ETF Indonesia Stated-Owned Companies lebih besar dari sisi kapitalisasi pasar. Mana yang lebih baik tergantung tujuan investasimu.
| INAF | XISC | |
|---|---|---|
Kapitalisasi Pasar | 390,51 M | 719 M |
Volume | — | 1,6 rb |
Lot | — | 16 |
Perputaran | — | 1,29 jt |
Harga Rata-rata | — | 809,13 |
Nilai Transaksi | — | 1,29 jt |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Indofarma Tbk.
PT Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk (the Company) was established based on Deed No. 1 dated January 2, 1996 as amended by Deed No. 134 dated January 26, 1996 both of Notary Sutjipto, SH. PT. Indofarma, Tbk began as medicine factory well known as "Pabrik Obat Manggarai". Then take over by Japan's Government from Nederland's Government on 1942. On 1950 the Indonesian Government acquisited the factory by Department of Health and functioned as center of pharmacy production for its department. On 1979 the name changed to be Department of Health Center of Pharmacy Production as non Profit institution as main assignment to produced medicine for public service. Then the Company changed the name as PT. Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk.
Selengkapnya di halaman INAF →
